Why Biotech Stocks Will Outperform in 2016 – and Our Top Pick

Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date. Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days. But first, here's why biotech stocks are presenting a huge opportunity right now... Tags: Best Biotech Stocks , biotech investing , biotech stock , biotech stocks , biotech stocks 2016 , biotech stocks to buy , biotechs , top biotech stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2016 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Biotech Stocks Will Outperform in 2016 – and Our Top Pick appeared first on Money Morning - We Make Investing Profitable .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.